Allogene Therapeutics
ALLO
209 hedge funds and large institutions have $652M invested in Allogene Therapeutics in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 99 increasing their positions, 49 reducing their positions, and 30 closing their positions.
165% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $413K
102% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 49
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
47% more capital invested
Capital invested by funds: $445M → $652M (+$207M)
15.03% more ownership
Funds ownership: 75.56% → 90.58% (+15%)
7% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 30
0% more funds holding
Funds holding: 209 → 209 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$41M |
| 2 |
SCM
Sio Capital Management
New York
|
+$29.3M |
| 3 |
BlackRock
New York
|
+$24.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.47M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.71M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.89M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
-$2.69M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.63M |
ALLO Hedge Fund Activity: Q2 2026 in Review
209 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2026, worth a combined $652M — up 47% from $445M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ALLO positions and 30 closed out — a net gain of 2 holders — while 99 added to existing stakes and 49 trimmed.
The largest buyer was Frazier Life Sciences Management, adding an estimated $41M. The largest seller was MPM BioImpact, exiting entirely with an estimated $5.47M sold.
- 209 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $652M of Allogene Therapeutics stock for Q2 2026, up 47% quarter-over-quarter.
- 32 funds opened new Allogene Therapeutics positions in Q2 2026 and 30 closed out, a net change of +2 holders.
- The largest Allogene Therapeutics buyer in Q2 2026 was Frazier Life Sciences Management, an estimated $41M added.
- The largest Allogene Therapeutics seller in Q2 2026 was MPM BioImpact, an estimated $5.47M sold.
Based on aggregated 13F filings for Q2 2026.